Primary CD8+ T cell activation markers and checkpoint inhibitors 48 hours after exposure to SKOV3 tumor cells and various IgGs and IgG BsAbs (10:1 E:T). Results were similar for CD4+ T cell activation markers and checkpoint inhibitors
| Test article | CD69 (%+) | CD25 (%+) | PD-1 (%+) | 4-1BB (%+) | CTLA-4 (%+) |
| IgG1 control 0.1 nM | 2.7 | 0 | 1 | 0.2 | 0 |
| IgG1 control 0.01 nM | 2.3 | 0.1 | 0.8 | 0.1 | 0 |
| IgG1 control 0.001 nM | 2.1 | 0.6 | 1.2 | 0 | 0 |
| SP34 IgG1_N297Q 0.1 nM | 32.7 | 2.4 | 1.7 | 2.2 | 0 |
| SP34 IgG1_N297Q 0.01 nM | 5.8 | 0.1 | 1.7 | 0.2 | 0 |
| SP34 IgG1_N297Q 0.001 nM | 1.8 | 0 | 1.4 | 0 | 0 |
| Pertuzumab IgG1 0.1 nM | 1.5 | 0 | 1 | 0 | 0 |
| Pertuzumab IgG1 0.01 nM | 2.1 | 0.1 | 1.1 | 0 | 0 |
| Pertuzumab IgG1 0.001 nM | 2.5 | 0.2 | 1.3 | 0 | 0 |
| SP34+Pertuz IgGs 0.1 nM | 26.1 | 1.4 | 1.8 | 3.7 | 0 |
| SP34+Pertuz IgGs 0.01 nM | 4.3 | 0.2 | 1.3 | 0.1 | 0.1 |
| SP34+Pertuz IgGs 0.001 nM | 1.7 | 0.1 | 1 | 0 | 0.1 |
| SP34/Pertuz IgG BsAb 0.1 nM | 96.7 | 85.7 | 75.7 | 85.3 | 9.5 |
| SP34/Pertuz IgG BsAb 0.01 nM | 84.7 | 65.5 | 51.7 | 79.7 | 3.5 |
| SP34/Pertuz IgG BsAb 0.001 nM | 44.4 | 16.1 | 11.2 | 19.7 | 0.4 |
| SP34_F100fH/Pertuz IgG BsAb 0.1 nM | 87.5 | 73.8 | 56 | 80.9 | 2.3 |
| SP34_F100fH/Pertuz IgG BsAb 0.01 nM | 46.6 | 18.1 | 10.4 | 15.7 | 0.2 |
| SP34_F100fH/Pertuz IgG BsAb 0.001 nM | 3 | 0 | 0.9 | 0.2 | 0.1 |
BsAb, bispecific antibody; PD-1, Programmed cell death 1.